Get great ideas from our AI, cannabis, cleantech, crypto, esports and mining podcasts - be a guest or sponsor : 800 665 0411

Share on StockTwits

Cannabis Deal Tracker: Investment and M&A Activity in the Cannabis Industry October 5th - October 9th, 2020


October 14, 2020 ( Newswire) KEY INSIGHTS & TAKEAWAYS


  • Transactional Activity: Week 41 ended October 9th, 2020, was a relatively light week in cannabis capital raises with a $51.6 million lower dollar volume with one more transaction vs. the prior week of this year and a 90.0% lower dollar volume with 1 fewer transaction vs the prior-year period. We tracked 6 capital raise transactions totaling $8.25 million, vs 7 transactions totaling $82.6 million during the same week in 2019. The average tranche size was $1.4 million this week, vs. $11.8 million in the prior-year period.
  • Largest Cap Raise: On October 7, 2020, Elixxer Ltd. (TSX: ELXR) (OTCQB: ELIXF), a cannabis investment company with significant interests in Australia, Jamaica, Switzerland, Italy, and Canada, raised C$4.0 million (US$3.02 mill.) from AIP Convertible Private Debt Fund L.P. in a secured two-year term loan with an interest rate of 17%. The eye-popping rate is only one of the features that make this deal expensive. A combination of C$200,00 in facility fees, C$250,000 in closing fees, C$75,000 in due diligence fees, and 46.3 million shares were paid to the lender, and the total value of these fees and shares totaled approximately 24.7% of the gross proceeds. Treating these amounts as an OID, we calculate the effective cost of this loan to be 34.6%. The Viridian Credit Tracker ranks Elixxer #14 out of the 22 Canadian Investment sector companies with market caps under US$25 million that we track. The company ranks #17 on our leverage measure; however, this transaction, by increasing proforma debt by 50% and increasing proforma liabilities-to-market-cap to 2.8X, would push its leverage ranking to #18.
  • Public vs. Private Cap Raises: 4 of this week's 6 capital raises were closed by public companies. So far in 2020, public companies have accounted for 80% of all capital raises, vs. 66% for the same period in 2019. In 2020, public companies have accounted for 84% of total dollars raised, vs. 69% for the same period in 2019.
  • Public Company Listings: Of the 4 public company capital raises, all are listed in Canada on (3 on the CSE and 1 on the TSX), and all 4 also trade in the U.S. on the OTC.
  • Equity vs. Debt Cap Raises: Equity-based capital raises accounted for 5 of this week's 6 capital raises and accounted for 63% of the funds raised.
  • Largest Equity Capital Raise: On October 9, 2020, Deep Desert Beverage, Inc., a private new entrant into the THC-infused drink market, raised US$1.65 million in a Series B funding round. Proceeds will be used to finance the buildout of the company's Nevada City facility and prepare the company for a planned product launch in the first quarter of 2021.
  • Cap Raises by Sector: The 6 capital raises this week were spread across 4 different industry sectors with two in Software/Media, two in Investment/ M&A, one in Biotech, and one in Infused Products & Extracts.


  • Transactional Activity: Week 41 saw 1 M&A transaction, down from 5 in the prior-year period. Although the number of M&A transactions completed year-to-date is down 77% vs the comparable period of 2019, we continue to expect increased activity in the remainder of the year.
  • Largest M&A Transaction: On October 7, CB2 Insights (CSE: CBII) (OTCQB: CBIIF) (“CB2”), “one of the largest integrative healthcare systems in the United States” closed its acquisition of Texas-based Maverick County Medical, a primary care medical and wellness clinic with about 10,300 patients. CB2 plans to leverage its current telemedicine infrastructure to provide access to patients across Texas. The total purchase consideration of C$0.98 million (US$0,74 mill.) will be paid in cash, 50% at closing, and 50% following 6 months from the date of the transaction. The purchase price represents .61 times 2019 revenue and 3.4 times 2019 net income. The acquisition follows closely after a US$3.8 million CB2 private placement of equity In September 2020. CB2's stock price is up over 200% YTD.
  • Public vs. Private: This week's sole acquisition was made by a public company. Year-to-date, 92% of M&A transactions closed in 2020 have been made by public companies (up from 71% in 2019). Public companies, particularly with the recovery in stock prices and fundraising ability, have been the dominant acquirers in the cannabis industry. Private companies remain the dominant targets for acquirers.
  • M&A by Sector: The buyer in this week's deal came from Software/Media sector, while the target was from the Miscellaneous Ancillary sector.


The Viridian Cannabis Deal Tracker is a proprietary information service that monitors capital raise and M&Amp;Amp;A activity in the legal cannabis and hemp industry. Each week the Tracker aggregates and analyzed all closed deals and segments each according to key metrics:

  • Industry Sector (one of 12 sectors, from Cultivation to Brands)
  • Dollar value of the transaction
  • Region in which the deal occurred (country or U.S. state)
  • Status of the company announcing the transaction (Public vs. Private)
  • Deal structure (equity vs. debt)
  • Key deal terms

The Viridian Cannabis Deal Tracker provides the market intelligence that cannabis companies, investors, and acquirers utilize to make informed decisions regarding capital allocation and M&Amp;Amp;Amp;A strategy.

Since its inception in 2015, the Viridian Cannabis Deal Tracker has tracked and analyzed more than 2,500 capital raises and 1,000 M&Amp;Amp;Amp;A transactions totaling over $45 billion in aggregate value.

*Copyright © 2020 by Viridian Capital Advisors

All rights reserved. No part of this publication may be reproduced, distributed, or transmitted in any form or by any means, including photocopying, recording, or other electronic or mechanical methods, without the prior written permission of the publisher, except in the case of brief quotations embodied in critical reviews and certain other noncommercial uses permitted by copyright law. For permission requests, write to the publisher. No part of this material may be (I) copied, photocopied, or duplicated in any form, by any means, or (II) redistributed without Viridian's prior written consent.


The information contained herein is for informational purposes and is not intended as a research report. It should not be construed as Viridian recommending investment in cannabis companies or as a solicitation to buy or sell any security or engage in a particular investment strategy. Investment in cannabis companies entails substantial risk. Before acting on any information, you should consider whether it is suitable for your particular circumstances and consult all available material, and, if necessary, seek professional advice.

Viridian Capital Advisors and its affiliates, as well as their respective partners, directors, shareholders, and employees, may have a position in the securities mentioned herein or may make purchases and/or sales from time to time. Viridian Capital Advisors, through broker-dealer services provided by Bradley Woods & Co. Ltd., (Member FINRA/SIPC), may act, or may have acted in the past, as a financial advisor to certain companies mentioned herein and may receive, or may have received, a remuneration for their services from those companies.

The above information whether in part or in its entirety neither constitutes an offer nor makes any recommendation to buy or sell any securities.

About Viridian Capital Advisors, LLC

Viridian Capital Advisors ( is a financial and strategic advisory firm dedicated to the cannabis market. We are a data- and market intelligence-driven firm that provides investment, M&Amp;Amp;A, corporate development, and investor relations services to emerging growth companies and qualified investors in the cannabis sector. Our banking practice, through broker-dealer Bradley Woods & Co. Ltd. (Member FINRA/SIPC), provides capital and M&Amp;Amp;A services to fund the growth of our clients, while our advisory practice helps to position and build their businesses. Our team's decades of high level operating and transactional experience on Wall Street in a variety of emerging sectors, allows Viridian to provide comprehensive strategic and financial solutions that assist cannabis enterprises in realizing their full potential.

Marijuana remains illegal under federal law. The federal government does not recognize marijuana to have any medicinal value. Marijuana cultivation, possession, consumption, sales, and distribution are illegal under federal laws and also certain state laws. Investors in cannabis may be subject to law enforcement actions. Please note that there are differences in marijuana laws from one state, county, or city to another. Furthermore there are substantial risks associated with investing in cannabis companies, including, without limitation, changes in applicable laws, rules, and regulations, risks associated with the economic environment, the financing markets, and risks associated with a company's ability to execute on its business plan.

Contact Us:

Viridian Capital Advisors, LLC

Disclaimer/Disclosure: is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions.

More disclaimer info: Learn more about publishing your news release and our other news services on the newswire and

Global investors must adhere to regulations of each country. Please read privacy policy:

Follow Us on StockTwits

Get more Cannabis Stock Investor Ideas - news, articles, podcasts and stock directories for Cannabis stocks and Psychedelic Stocks

Buy a cannabis guest post on


Sign up for free stock news alerts at